Johnson & Johnson (JNJ) Price & Analysis

Compare

149 Followers

JNJ Stock Chart & Stats

€206.65

-€0.18(-0.13%)

At close: Jan 09 4:00 PM EST

€206.65

-€0.18(-0.13%)

Day’s Range― - ―

52-Week Range€128.16 - €214.85

Previous CloseN/A

Volume223.00

Average Volume (3M)3.56K

Market Cap

€489.34B

Enterprise Value€596.04B

Total Cash (Recent Filing)€20.10B

Total Debt (Recent Filing)€47.93B

Price to Earnings (P/E)18.8

Beta0.24

Next Earnings

Apr 14, 2026

EPS Estimate

2.34

Next Dividend Ex-DateN/A

Dividend Yield2.54%

Share Statistics

EPS (TTM)2.14

Shares Outstanding2,409,899,000

10 Day Avg. Volume3,974

30 Day Avg. Volume3,563

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)6.18

Price to Sales (P/S)5.35

P/FCF Ratio25.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€221.74

Price Target Upside7.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering16

EPS Forecast (FY)9.99

Revenue Forecast (FY)€86.99B

Bulls Say, Bears Say

Bulls Say

Pipeline ExpansionInitiation of Phase three trials in ulcerative colitis and Crohn's and a head-to-head study versus Stelara offers opportunities to expand Icotyde's label into additional inflammatory diseases, supporting future revenue upside.

Product Commercial SynergyStrong clinical data for Tecvayli and evidence that combined use extends Darzalex treatment support increased commercial potential in multiple myeloma and justify higher sales expectations for related therapies.

Regulatory ApprovalFDA approval of Icotyde as a first-in-class oral interleukin inhibitor for moderate-to-severe plaque psoriasis creates a new product cycle that can boost growth and broaden patient access compared with injectable competitors.

Bears Say

Competitive EfficacyPerception that injectable interleukin therapies are more effective could limit Icotyde's market share and slow adoption versus established injectable drugs.

Litigation RiskOngoing talc and other litigation exposures remain unresolved and could result in material costs or sustained investor caution that constrains stock upside.

Pricing And Access UncertaintyLimited visibility on Icotyde's pricing and patient access strategy creates uncertainty about revenue realization and may delay the expected sales ramp.

Johnson & Johnson News

Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)

WSW, NY, March 5th, 2026, FinanceWire As Washington pushes cheaper medicines through TrumpRx, Mark Cuban challenges the pharmaceutical...

17d ago

AZN

IBO

IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors

Specialization can lead to big gains. ...

3d ago

BSX

IHE

Johnson & Johnson price target raised to $234 from $217 at Barclays

Barclays raised the firm’s price target on Johnson & Johnson to $234 from $217 and keeps an Equal...

3d ago

JNJ

Icotyde label upside surprise for Protagonist, says H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao says that while Icotyde’s approval was expected, the earlier than expected approval and...

4d ago

JNJ

PTGX

Trump Trade: President issues short-term waiver of Jones Act

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

4d ago

AZN

BMY

Trump claims TrumpRx website offers lowest prices, review says not so, NYT says

President Trump and top federal health officials have repeatedly claimed that their new website, TrumpRx, offers Americans the...

4d ago

AZN

BMY

Protagonist announces Johnson & Johnson received approval for ICOTYDE

Protagonist Therapeutics (PTGX) announced that Johnson & Johnson (JNJ) received FDA approval for ICOTYDE, or icotrokinra, an interleukin-23...

4d ago

JNJ

PTGX

Johnson & Johnson announces U.S. FDA approved Icotyde

Johnson & Johnson announced that the U.S. Food and Drug Administration, FDA, has approved Icotyde, an interleukin-23 receptor...

4d ago

JNJ

Judge overturns $950M talc trial award against Johnson & Johnson, Reuters says

A California judge has overturned a jury’s decision ordering Johnson & Johnson to pay nearly $1B in punitive...

4d ago

JNJ

Johnson & Johnson price target raised to $280 from $245 at UBS

UBS analyst Danielle Antalffy raised the firm’s price target on Johnson & Johnson to $280 from $245 and...

5d ago

JNJ

Johnson & Johnson price target raised to $280 from $265 at HSBC

HSBC analyst Morten Herholdt raised the firm’s price target on Johnson & Johnson to $280 from $265 and...

5d ago

JNJ

District court rules federal limits to vaccines not based on science, NYT says

Bostong U.S. District Judge Brian Murphy on Monday has sided with medical groups who argued that HHS Secretary...

5d ago

AZN

BMY

3 Best ETFs to Invest In, According to AI Analyst, 03/16/2026

Although the ongoing conflict in the Middle East has left investors on constant alert, exchange-traded funds remain among...

5d ago

JNJ

PEP

Best ETFs to Invest In, According to AI Analyst, 3/11/2026

As global markets remain volatile due to the ongoing U.S.-Iran war, investors can consider adding exchange-traded funds (ETFs)...

10d ago

BAC

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was €128.16 and its highest was €214.85 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is €489.34B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Apr 14, 2026 which is in 23 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Jan 21, 2026. The company reported €2.144 earnings per share for the quarter, missing the consensus estimate of €2.146 by -€0.003.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of €1.124 which represents an annual dividend yield of 2.54%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.34.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,899,000 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of €2.144 in its last earnings report, missing expectations of €2.146. Following the earnings report the stock price went down -1.197%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in DE:JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Neutral

Fundamentals

Return on Equity

33.78%

Trailing 12-Months

Asset Growth

10.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights a dominant message of accelerating, portfolio-driven growth: robust revenue and adjusted EPS growth, strong free cash flow, numerous approvals and late-stage programs, and notable commercial momentum across oncology, immunology, neuroscience, and MedTech. Management provided constructive 2026 guidance, reiterated long-term ambition (double-digit growth by the end of the decade), and outlined capital deployment and the orthopedics separation. Offsetting risks include material STELARA biosimilar erosion (a substantial multi-hundred-basis-point headwind), elevated litigation and one-time charges, tariff pressures, competitive dynamics in select MedTech areas, and modest share-count dilution. On balance, the positives — broad-based commercial strength, pipeline and approval milestones, robust cash generation, and clear guidance — materially outweigh the near-term headwinds.View all DE:JNJ earnings summaries

JNJ Sales Breakdown

64.12% Innovative Medicine

35.88% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

€221.74

▲(7.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"129":"€129","158":"€158","187":"€187","216":"€216","245":"€245"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":244.5660476,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€244.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":221.7427946579,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€221.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":192.1590374,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€192.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[129,158,187,216,245],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,212.6,215.05892673846154,217.51785347692308,219.97678021538462,222.43570695384614,224.89463369230768,227.35356043076922,229.81248716923076,232.2714139076923,234.73034064615385,237.1892673846154,239.6481941230769,242.10712086153845,{"y":244.5660476,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,212.6,213.30329189676152,214.00658379352308,214.7098756902846,215.41316758704616,216.1164594838077,216.81975138056922,217.52304327733077,218.2263351740923,218.92962707085383,219.63291896761538,220.3362108643769,221.03950276113846,{"y":221.7427946579,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,212.6,211.02761826153846,209.4552365230769,207.88285478461538,206.31047304615385,204.7380913076923,203.16570956923076,201.59332783076923,200.0209460923077,198.44856435384614,196.8761826153846,195.30380087692308,193.73141913846152,{"y":192.1590374,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":152.866,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.261,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.757,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.816,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.903,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.391,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.401,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.701,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.766,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.994,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >